Novo Nordisk's (NVO) blockbuster diabetes drug, Ozempic (semaglutide), reduced the risk of kidney disease progression in a late-stage trial, the company announced on Tuesday. Initiated in 2019 ...

(Bloomberg) -- Novo Nordisk A/S’s blockbuster diabetes drug Ozempic cut patients’ risk of dying in a kidney-disease study, the latest research pointing to the medicine’s usefulness in a ...

Novo Nordisk has halted a phase 3 trial of its Ozempic formulation of GLP-1 agonist semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) early after signs of a clear ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney ...

Mahaffey focused on Novo Nordisk’s Ozempic (semaglutide) to highlight the progress made in glucagon-like peptide-1 (GLP-1) for the management of CKD. The results presented at ESC showed that the ...

The FDA has received reports of at least 20 cases of ileus, including two deaths, among people taking Ozempic. The agency ordered that the drugmaker, Novo ... Ozempic and kidney disease The ...

Ozempic, the highly popular GLP-1 agonist drug touted by many celebrities for weight loss, is in short supply, according to its drug maker Novo Nordisk ... nerve damage, kidney disease and ...

Promising early data from an experimental trial of a new obesity treatment pill has sent shares of Danish pharmaceutical Novo Nordisk skyrocketing, Bloomberg reports. The drug, called amycretin ...

More Tennessee companies are covering weight-loss injections in health care benefit plans. This could impact the state's high ...

Three scientists are honoured for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

Novo Nordisk (NYSE: NVO ... which targets APOL1-mediated kidney disease (AMKD). There are no current therapies approved for treating the underlying cause of AMKD, which affects more patients ...